Amgen Inc (AMGN) Ordinary US $ 0.01

Sell:$310.72Buy:$310.90$0.43 (0.14%)

Dow Jones:1.48%
Market closed | Prices delayed by at least 15 minutes
Sell:$310.72
Buy:$310.90
Change:$0.43 (0.14%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$310.72
Buy:$310.90
Change:$0.43 (0.14%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

Key people

Robert A. Bradway
Chairman of the Board, President, Chief Executive Officer
Peter H. Griffith
Chief Financial Officer, Executive Vice President
David M. Reese
Executive Vice President, Chief Technology Officer
James Bradner
Executive Vice President, Research and Development, and Chief Scientific Officer
Jonathan P. Graham
Executive Vice President, General Counsel, Secretary
Murdo Gordon
Executive Vice President - Global Commercial Operations
Esteban Santos
Executive Vice President - Operations
Nancy A. Grygiel
Senior Vice President, Chief Compliance Officer
Derek Miller
Senior Vice President of Human Resources
Rachna Khosla
Senior Vice President - Business Development
Robert A. Eckert
Lead Independent Director
Mary E. Klotman
Director
Wanda M. Austin
Independent Director
Michael V. Drake
Independent Director
Brian J. Druker
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US0311621009
  • Market cap
    $165.49bn
  • Employees
    28,000
  • Shares in issue
    537.20m
  • Exchange
    NASDAQ
  • Index
    Dow Industry, S&P 500, NASDAQ 100 Index, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.